Biontech/Pfizer
U.S. Emergency Use Authorization Pending for Omicron Vaccine
Syringe with the vaccine from Biontech. photo
© Kay Nietfeld/dpa
According to Biontech/Pfizer, it could start delivering a corona vaccine adapted to the Omicron variants BA.4 and BA.5 as early as September. However, approval is a prerequisite.
The German pharmaceutical company Biontech and its US partner Pfizer have applied to the US Food and Drug Administration (FDA) for emergency authorization for a corona vaccine adapted to the currently circulating omicron variants BA.4 and BA.5. The two companies announced on Monday that an application for the European Medicines Agency Ema should also be completed in the coming days.
With the appropriate approvals, delivery could begin as early as September, it said. However, there is still no clinical study on the adapted variant. The companies had previously submitted applications for a vaccine adapted to the BA.1 subtype. In Germany, this variant no longer plays a role.
Message